PTI has been awarded a Phase 1 SBIR for research toward "Receptor-targeted Neuroendocrine Tumor Imaging with Generator-produced Cu-62" in collaboration with Dr. Mark Green and Dr. James Fletcher of Indiana University. This project will pair key expertise from PTI in radionuclide production and distribution with Indiana University's experience in receptor-targeted whole-body PET/CT imaging. The proposed outcome of this research, post FDA approval, is for the PET imaging field to have access to clinical-grade generator-produced Cu-62 radionuclide and associated kits for on-site compounding of important cancer diagnostic agents. Successful outcomes in this research would pave the way for increased availability of PET imaging procedures in clinics and significantly reduced cost-per-dose for medical facilities that do not have their own radionuclide production capabilities.
Whole-Body PET/CT Evaluation of Tumor Perfusion Using Generator-Based 62Cu-Ethylglyoxal Bis(Thiosemicarbazonato)Copper(II): Validation by Direct Comparison to 15O-Water in Metastatic Renal Cell Carcinoma. J. Nucl Med 56:56-62; 2015.
Experience in Production of 68Ga-DOTA-NOC for Clinical Use Under an Expanded Access IND. Applied Radiation and Isotopes 116:63-68; 2016.
Performance of a 62Zn/62Cu microgenerator in kit-based synthesis and delivery of [62Cu]Cu–ETS for PET perfusion imaging. Applied Radiation and Isotopes, 91: 38-43; 2014.